Literature DB >> 23688495

Prescribers and pharmacists requests for prescription monitoring program (PMP) data: does PMP structure matter?

Marc L Fleming1, Hitesh Chandwani, Jamie C Barner, Stephanie N Weber, Tony T Okoro.   

Abstract

Prescription monitoring programs (PMPs) have been purported to be an effective tool to combat prescription drug abuse. However, utilization rates of PMP data by health care providers (e.g., prescribers and pharmacists) is relatively low. The objectives of the study were to describe (1) PMP utilization (e.g., requested reports) by prescribers, pharmacists, and law enforcement for active state PMPs; (2) PMP utilization by health care providers with and without online access; (3) average annual operational costs for PMPs from 2008 to 2009; and (4) PMP requests based on PMP housing authority (law enforcement vs. non-law enforcement [e.g., board of pharmacy]). This was a cross-sectional study employing a Web-based survey. A 16-item questionnaire was e-mailed to the 33 operational state PMP administrators and responses were collected from January to March 2011. Descriptive statistics were used to describe PMP request rates and annual operating costs. The usable survey response rate was 45.5%. Among all authorized users, prescribers had higher mean (±SD) requests per 100,000 population (2198.2 ± 3218.0) compared with pharmacists' requests (268.9 ± 261.2). Online accessibility resulted in higher request rates per 100,000 population (2996.4 ± 3021.5) compared with mail/fax access (14.6 ± 2.8). On average, PMP annual costs were $12,515 ± $14,911 per 100,000 population. In law enforcement-governed PMPs, health care provider utilization was lower compared with PMPs under health or pharmacy boards. Prescriber request rates were higher than pharmacists and online access for providers (e.g., prescribers and pharmacists) resulted in higher request rates per 100,000 population. More research is needed to determine other factors that may be associated with PMP utilization by prescribers and pharmacists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23688495     DOI: 10.3109/15360288.2013.788598

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  10 in total

1.  Systematic Literature Review of Prescription Drug Monitoring Programs.

Authors:  Aditya Ponnapalli; Adela Grando; Anita Murcko; Pete Wertheim
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

2.  Clinicians' Use of Prescription Drug Monitoring Programs in Clinical Practice and Decision-Making.

Authors:  Gillian J Leichtling; Jessica M Irvine; Christi Hildebran; Deborah J Cohen; Sara E Hallvik; Richard A Deyo
Journal:  Pain Med       Date:  2017-06-01       Impact factor: 3.750

3.  Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998-2011.

Authors:  Corey S Davis; Matthew Pierce; Nabarun Dasgupta
Journal:  Am J Public Health       Date:  2014-06-12       Impact factor: 9.308

4.  Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians.

Authors:  Jessica M Irvine; Sara E Hallvik; Christi Hildebran; Miguel Marino; Todd Beran; Richard A Deyo
Journal:  J Pain       Date:  2014-04-29       Impact factor: 5.820

5.  Leading a Horse to Water: Facilitating Registration and Use of a Prescription Drug Monitoring Program.

Authors:  Richard A Deyo; Jessica M Irvine; Sara E Hallvik; Christi Hildebran; Todd Beran; Lisa M Millet; Miguel Marino
Journal:  Clin J Pain       Date:  2015-09       Impact factor: 3.442

6.  Prescription drug abuse communication: A qualitative analysis of prescriber and pharmacist perceptions and behaviors.

Authors:  Nicholas E Hagemeier; Fred Tudiver; Scott Brewster; Elizabeth J Hagy; Angela Hagaman; Robert P Pack
Journal:  Res Social Adm Pharm       Date:  2015-12-29

7.  Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.

Authors:  Patricia R Freeman; Geoffrey M Curran; Karen L Drummond; Bradley C Martin; Benjamin S Teeter; Katharine Bradley; Nancy Schoenberg; Mark J Edlund
Journal:  Res Social Adm Pharm       Date:  2018-09-14

8.  The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability.

Authors:  Michael E Schatman; Lynn R Webster
Journal:  J Pain Res       Date:  2015-03-18       Impact factor: 3.133

9.  Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin.

Authors:  Julia Dickson-Gomez; Erika Christenson; Margaret Weeks; Carol Galletly; Jennifer Wogen; Antoinette Spector; Madelyn McDonald; Jessica Ohlrich
Journal:  Subst Abuse       Date:  2021-03-25

10.  Health Care Provider Utilization of Prescription Monitoring Programs: A Systematic Review and Meta-Analysis.

Authors:  Alysia Robinson; Maria N Wilson; Jill A Hayden; Emily Rhodes; Samuel Campbell; Peter MacDougall; Mark Asbridge
Journal:  Pain Med       Date:  2021-07-25       Impact factor: 3.750

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.